This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

COSA - Adelaide, Australia, 12 – 14 November 2019

Xentuzumab (BI 836845), an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive locally advanced/metastatic breast cancer: randomised Phase II results

John Crown, Marie-Paule Sablin, Javier Cortés, Seock-Ah Im, Yen-Shen Lu, Noelia Martínez, Patrick Neven, Keun Seok Lee, Serafín Morales, J. Alejandro Pérez-Fidalgo, Douglas Adamson, Anthony Gonçalves, Aleix Prat, Guy Jerusalem, Laura Schlieker, Rosa-Maria Espadero, Thomas Bogenrieder, Dennis Chin-Lun Huang, Peter Schmid

crown_1280.4_cosa-asm_poster

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

XENERA™-1: A Phase II trial of xentuzumab in combination with everolimus and exemestane in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer and non-visceral involvement

Peter Schmid, Hope S. Rugo, Javier Cortés, Dennis Chin-Lun Huang, Kate Crossley, Dan Massey, Howard A. Burris III

 

schmid_1280.22_tip_cosa-asm_poster

FOR HEALTHCARE PROFESSIONALS ONLY

links_to_3rd_party.jpg